Replies to post #803806 on NorthWest Biotherapeutics Inc (NWBO)

[learningcurve2020]

That’s exactly what’s happening with L patients, as well.

>>What typically happens is there will be some initial improvement but then the cancer returns with vengeance as it mutates into a form without those select antigens.

[dstock07734]

It's not a matter of one target or a wide spectrum of targets. It is a matter of how the targets are being approached.

We can see H3 G34 is chosen as the target to treat brain tumor in a clinical trial. We can see FRalpha family was chosen as the target in DC vaccine trials conducted by Mayo Clinic. We can also see that HER2 was chosen as the single target in DC trials conducted at Moffitt Cancer Center.

What's really critical in designing ADCs is the identification of tumor-specific antigens that can be loaded on ADCs and DCVAX-L can identify those tumor-specific antigens easily and efficiently, which was shown in Dr. Bosch's ASCO presentation in June 2023.

The above is my conjecture though.

What really intrigues me is whether Pfizer, Merck, and Baker Brothers knew about those DC vaccine trials which had pneumococcal vaccine adopted in the combination before the acquisition of Seagen happened. I can smell the Art of War in play!

[sentiment_stocks]

What typically happens is there will be some initial improvement but then the cancer returns with vengeance as it mutates into a form without those select antigens.

Exactly… for example, Rindopepimut targeted EGFRvIII, and when the tumor(s) treated with the rindo vaccine returned to kill the patient, the egfrv3 was gone.